- Home
- EQBK vs SPRY Comparison
EQBK vs SPRY Comparison
Compare EQBK & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQBK | SPRY |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.4M | 823.2M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EQBK | SPRY |
|---|---|---|
| Price | $45.00 | $8.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $51.33 | $40.00 |
| AVG Volume (30 Days) | 86.1K | ★ 1.6M |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $74.58 | $87.40 |
| Revenue Next Year | $5.11 | $81.64 |
| P/E Ratio | $56.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.04 | $6.66 |
| 52 Week High | $50.07 | $18.63 |
Technical Indicators
Market Signals| Indicator | EQBK | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 53.77 |
| Support Level | $44.41 | $8.61 |
| Resistance Level | $47.75 | $9.46 |
| Average True Range (ATR) | 0.81 | 0.48 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 23.81 | 53.91 |
Price Performance
Historical ComparisonAbout EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.